BridgeBio Pharma Inc. has bolstered its financial position by securing $300 million through a partial monetization of European royalties for its drug, BEYONTTRA. This strategic move involves selling 60% of royalties on the first $500 million of annual net sales in Europe, capped initially at 1.45x, with funds managed by HCRx and Blue Owl. The transaction supports the launch of Attruby and the development of BridgeBio's late-stage pipeline programs. BEYONTTRA, known as Attruby in the U.S., is approved for treating ATTR-CM and reflects significant commercial potential. This expansion is further reinforced by an exclusive licensing agreement with Bayer Consumer Care AG for European commercialization, with BridgeBio set to receive milestone payments and tiered royalties.